Tebentafusp Shows Significant OS Benefit in Advanced Uveal Melanoma
Richard D. Carvajal, MD, discusses the mechanism of action and efficacy of tebentafusp-tebn for patients with uveal melanoma.
Early Trials in Melanoma Show Better Response After 1 Year
Richard D. Carvajal, MD, discusses 2 therapies in clinical trials registering patients with melanoma.
The Design of a Trial Analyzing Selumetinib in Advanced Uveal Melanoma
Richard D. Carvajal, MD, describes the design of a phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma.
Using Selumetinib in Advanced Uveal Melanoma
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.